Profile data is unavailable for this security.
About the company
InnoCare Pharma Ltd is a China-based company mainly engaged in the research and development, production and commercialization of biopharmaceuticals. The Company focuses on areas with large unmet clinical needs, such as oncology and autoimmune diseases. The Company's primary product pipeline includes Orelabrutinib, Tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-B05, ICP-332, ICP-488, ICP-192, ICP-723, ICP-033 and ICP-189, and others. Its products are mainly used to treat hematological tumors, solid tumors and autoimmune diseases. The Company is also developing products for the treatment of autoimmune diseases caused by abnormal B cell or T cell function. The Company mainly conducts its businesses in domestic and overseas markets.
- Revenue in CNY (TTM)714.97m
- Net income in CNY-761.26m
- Incorporated2015
- Employees1.09k
- LocationInnoCare Pharma LtdBuilding 8, No. 8Life Science Park Road, ZhongguancunLife Science Park, Changping DistrictBeijing 102206ChinaCHN
- Phone+86 1 066609999
- Fax+86 1 060702992
- Websitehttps://www.innocarepharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Guangxi Wuzhou Zhongheng Group Co Ltd | 3.23bn | 156.14m | 7.77bn | 2.89k | 49.54 | 1.18 | -- | 2.40 | 0.0454 | 0.0454 | 0.9413 | 1.91 | 0.2766 | 1.96 | 3.41 | 1,120,149.00 | 0.9542 | 2.26 | 1.51 | 3.38 | 53.66 | 72.05 | 3.45 | 7.27 | 2.38 | -- | 0.1795 | 45.67 | 14.10 | -1.26 | 6.69 | -32.76 | -4.56 | -30.12 |
| Lushang Freda Pharmaceutical Co Ltd | 4.20bn | 233.09m | 7.85bn | 3.65k | 33.67 | 1.93 | -- | 1.87 | 0.2293 | 0.2293 | 4.13 | 4.01 | 0.4446 | 0.8832 | 7.75 | 1,149,606.00 | 3.02 | 0.6992 | 5.84 | 5.12 | 48.44 | 20.23 | 6.79 | 3.45 | 2.67 | -- | 0.1251 | 40.33 | -64.65 | -12.29 | 567.44 | 13.36 | 44.40 | 14.87 |
| Vcanbio Cell & Gene Engineering Corp Ltd | 1.61bn | 109.23m | 7.85bn | 2.21k | 71.89 | 2.13 | -- | 4.88 | 0.2334 | 0.2334 | 3.44 | 7.88 | 0.3034 | 2.01 | 2.86 | 728,818.10 | 1.97 | 1.13 | 2.79 | 1.61 | 67.97 | 67.76 | 6.51 | 3.84 | 1.52 | 6.93 | 0.0284 | 0.00 | 2.24 | 3.78 | -5.78 | 12.43 | -7.11 | -- |
| Youcare Pharmaceutical Group Co Ltd | 4.04bn | 168.83m | 7.99bn | 3.18k | 47.25 | 2.18 | -- | 1.98 | 0.3757 | 0.3757 | 8.97 | 8.13 | 0.6518 | 2.07 | 4.09 | 1,269,471.00 | 2.76 | 7.11 | 4.15 | 11.65 | 59.54 | 64.14 | 4.24 | 8.07 | 1.42 | -- | 0.2079 | 60.95 | -7.61 | 1.05 | -44.84 | -7.16 | 23.40 | -- |
| Shenzhen Chipscreen Biosciences Co Ltd | 547.79m | 103.01m | 8.12bn | 1.06k | 77.23 | 4.80 | -- | 14.82 | 0.2578 | 0.2578 | 1.33 | 4.15 | 0.1761 | 1.66 | 3.97 | 518,248.70 | 2.14 | 1.32 | 2.61 | 1.54 | 86.99 | 93.29 | 12.17 | 6.97 | 2.99 | -- | 0.4037 | 0.00 | -1.18 | 28.81 | 408.09 | 23.31 | 10.23 | -- |
| InnoCare Pharma Ltd | 714.97m | -761.26m | 8.22bn | 1.09k | -- | 1.87 | -- | 11.50 | -0.4394 | -0.4394 | 0.4181 | 3.99 | 0.0716 | 1.11 | 3.73 | 656,541.30 | -7.78 | -- | -9.83 | -- | 83.17 | -- | -108.68 | -- | 4.14 | -12.60 | 0.0139 | -- | 18.09 | -- | 28.80 | -- | -- | -- |
| China Animal Husbandry Industry Co., Ltd | 5.47bn | 339.08m | 8.34bn | 4.33k | 24.60 | 1.49 | -- | 1.53 | 0.3321 | 0.3321 | 5.36 | 5.48 | 0.6331 | 4.13 | 4.89 | 1,264,384.00 | 3.33 | 6.23 | 4.71 | 9.01 | 18.95 | 24.29 | 5.26 | 8.69 | 1.86 | -- | 0.2017 | 31.20 | -8.24 | 4.04 | -26.73 | -0.6127 | 24.20 | -3.77 |
| Jinyu Bio-Technology Co Ltd | 1.58bn | 282.51m | 8.47bn | 1.65k | 29.21 | 1.50 | -- | 5.35 | 0.2588 | 0.2588 | 1.44 | 5.05 | 0.2365 | 2.06 | 1.98 | 956,543.20 | 4.09 | 4.82 | 4.79 | 5.68 | 57.97 | 58.78 | 17.28 | 19.91 | 3.33 | -- | 0.0043 | 36.41 | 4.55 | -3.37 | 34.63 | -17.77 | -12.92 | -25.56 |
| Nanjing Vazyme Biotech Co Ltd | 1.29bn | -15.12m | 8.55bn | 2.70k | -- | 2.12 | -- | 6.65 | -0.0368 | -0.0368 | 3.27 | 10.07 | 0.2191 | 0.9761 | 2.85 | 476,061.10 | -0.286 | 13.16 | -0.3724 | 15.92 | 71.31 | 70.50 | -1.31 | 23.92 | 2.97 | -- | 0.2154 | 32.20 | -63.97 | 49.74 | -111.94 | -- | 48.61 | -- |
| Aurisco Pharmaceutical Co Ltd | 1.30bn | 325.73m | 8.83bn | 1.52k | 27.09 | 4.25 | -- | 6.82 | 0.803 | 0.803 | 3.18 | 5.12 | 0.5404 | 1.17 | 4.99 | 852,082.90 | 13.57 | 12.40 | 16.46 | 14.33 | 56.90 | 51.26 | 25.12 | 23.05 | 1.72 | -- | 0.116 | 25.15 | 25.24 | 17.02 | 37.23 | 16.16 | 26.54 | -- |
Data as of Jun 14 2024. Currency figures normalised to InnoCare Pharma Ltd's reporting currency: Chinese Yuan Renminbi CNY
45.06%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 30.55m | 11.74% |
| Wanjia Asset Management Co., Ltd.as of 31 Dec 2023 | 25.00m | 9.61% |
| E Fund Management Co., Ltd.as of 31 Dec 2023 | 18.76m | 7.21% |
| China Fund Management Co., Ltd.as of 31 Dec 2023 | 12.40m | 4.77% |
| Bank of China Investment Management Co., Ltd.as of 31 Dec 2023 | 6.66m | 2.56% |
| ICBC Credit Suisse Asset Management Co., Ltd.as of 31 Dec 2023 | 5.94m | 2.28% |
| Beijing Gao Hua Shengzi Investment Management Co. Ltd.as of 30 Sep 2022 | 5.79m | 2.23% |
| Morgan Stanley Investment Management Ltd.as of 30 Sep 2022 | 5.75m | 2.21% |
| Da Cheng Fund Management Co., Ltd.as of 30 Sep 2022 | 3.46m | 1.33% |
| JPMorgan Asset Management (China) Co Ltd.as of 31 Dec 2023 | 2.92m | 1.12% |
More ▼
Data from 30 Sep 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
